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To the Editor:
Recently in the Journal of 
Thoracic Oncology, Bollig-Fischer 
et al.1 nicely characterized racial diver-
sity in the frequency of so-called action-
able mutations in non–small-cell lung 
cancer. Advanced sequence testing with 
the hope of identifying such abnormali-
ties has become part of a standard evalu-
ation of most metastatic non–small-cell 
lung cancers. By evaluating a large 
series, their report underscores ethical 
issues that will occasionally occur with 
incidentally discovered findings from 
these assays.
For example, the authors mention 
the discovery of a “rare single nucleo-
tide germ line variant.” Whereas in this 
case, the significance of the variant may 
be unknown, what should be done if a 
molecular abnormality is discovered, 
which definitely implies a hereditary 
cancer syndrome? Should obtaining 
informed consent from the patient before 
advanced sequencing include a discus-
sion of such possible findings?
Theirs was a retrospective study 
wherein the data were compiled accord-
ing to the “Helsinki Declaration and 
approved by the Wayne State University 
School of Medicine.” If an abnormality 
had been identified in a patient’s tumor, 
which is typically associated with an 
inherited cancer syndrome, should they 
contact that patient?
With next generation and other 
advanced sequencing techniques, 
uncertainties regarding the significance 
of certain molecular abnormalities 
found during sequencing (e.g., mod-
erate-penetrance susceptibility genes 
and variants of unknown significance) 
might occur. Also, even if subsequent 
germ line testing identifies a very spe-
cific germ line molecular abnormality 
associated with an inherited syndrome, 
penetrance of the phenotype might be 
largely unknown compared with the 
same result seen based on germ line 
testing done for a patient with a per-
sonal and family history suggesting the 
inherited syndrome (not incidentally 
discovered).
How do we advise patients 
of these possible outcomes of a test 
ordered to identify actionable molecu-
lar abnormalities when that test has the 
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To the Editor:
Dr. Sorscher’s letter or comments 
could be used as a conversation starter 
for many academic laboratories and 
Institutional Review Boards overseeing 
human subject research, about the pos-
sibility of identifying actionable molec-
ular abnormalities in genomic research 
using patient specimens. Upon reading 
his letter the first thoughts that came to 
my mind surround what it means for a 
cancer gene aberration to be actionable, 
considering clinical diagnostic labora-
tory practices and the guidelines set 
by regulatory agencies for genetic or 
molecular testing.
Under the framework of clinical 
genomic testing the objective of the 
test, be it a hereditary cancer panel (test-
ing for variants in DNA from blood or 
saliva) or somatic mutation panel (test-
ing DNA from tumor tissue), specifi-
cally categorizes the test and nature of 
the significance of potential test results. 
It can be seen that major testing provid-
ers generally operate in the space of one 
or the other, not both. Regulatory agen-
cies such as the College of American 
Pathologists rightly dictate that testing 
panels comprise only gene features, 
inherited allelic variants or somatic 
lesions that if identified have clinical 
utility, i.e., unequivocal evidence to 
be beneficial to understanding patient 
risk or prognosis, or to inform deci-
sion-making with regard to treatment. 
Of course the number of clinically 
useful or actionable targets is poten-
tially an ever evolving list and major 
stakeholders in the discussion include 
test developers and providers, clini-
cal/translational researchers, payers, 
consumers, and regulators. The use of 
high-throughput methods, such as next-
generation sequencing or cytogenomic 
approaches, in clinical laboratory mul-
tigene testing hold potential to capture 
a lot of data. But, irrespective of total 
base pairs sequenced or expanse of 
genomic elements in the preprocessed 
data, regulatory agencies hold that the 
specific mutations or variants being 
tested for and reported remain strictly 
defined. To this end bioinformatic 
methods and data quality control are 
spelled out in detail in clinical labora-
tory standard operating procedures and 
routinely reviewed.
In conducting genomic research 
on human specimens, it now strikes me 
that it would probably be useful for pre-
clinical researchers to be aware of the 
current state of clinical testing: know 
what specific cancer variant testing is 
being provided by industry-leading 
clinical laboratories and know the stan-
dards set by regulatory agencies; and 
thus be in tune with what it means for 
a cancer genetic aberration to be clini-
cally actionable. This will prepare an 
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with activating EGFR gene mutations: 
the Okayama Lung Cancer Study Group 
Trial 1001.” In this clinical trial, the 
authors assessed the efficacy of beva-
cizumab and gefitinib combination 
therapy in non–small-cell lung cancer 
(NSCLC) and proposed the promis-
ing conclusion that the combination 
therapy of bevacizumab and gefitinib is 
favorable. Although the study provided 
promising findings on the combination 
treatment for NSCLC, several latest 
findings should be further discussed and 
emphasized.
First, the tolerability of bevaci-
zumab among the elderly has caused 
a wide controversy. A recent trial con-
ducted by Bakogeorgos et al.2 validates 
the poor compliance and toxicity of 
elderly patients whose age is up to 70 
years in the first-line therapy. The results 
indicate that elderly patients were less 
likely to receive bevacizumab (7.5% 
versus 21.3%) compared with the non-
elderly patients. The trial reveals that 
elderly patients with NSCLC may have 
treatment disadvantages compared with 
younger counterparts in these trials. 
Similar result was also presented by the 
Eastern Cooperative Oncology Group 
4599 and PointBreak trials,3 in which 
patients aged up to 74 years have no 
more benefit than younger patients with 
the addition of bevacizumab and encoun-
ter severe adverse events. The poor toler-
ability is possible due to elderly people’s 
slow metabolite rate and poor compli-
ance. Consequently, the dosage and eli-
gibility criteria should be arranged to fit 
the elderly patient’s condition.
Second, the cost-effectiveness is 
an important component for economic 
evaluation in the future treatment. 
According to a systematic review,3 
bevacizumab has an incremental cost- 
effectiveness ratios (ICERs) greater 
than $150,000 per quality-adjusted 
life-year (QALY). In epidermal growth 
factor receptor–mutated advanced 
NSCLC, testing available tissue for 
target therapy can yield an ICER of 
$110,644 per QALY, and the rebiopsy 
yields an ICER of $122,219 per QALY. 
Gefitinib had an ICER of $19,214 
per QALY. However, recent clinical 
NSCLC guidelines were based on no 
cost-effective strategies. The treat-







investigator to know if the scope of their 
research or data analysis output over-
laps. It is highly unlikely that genomic 
researchers investigating somatic tumor 
mutations would find a situation where 
contacting a patient’s physician would 
be called for, this type of research most 
often uses archived specimens at a time 
point well past when the information 
would be of use to strategizing treat-
ment. However, for research that covers 
hereditary factors or more specifically 
established risk variants using DNA 
from a noncancer tissue source, the 
original consent or a follow-up letter 
should ask if the consenting individual 
or members of their family choose to 
be informed in the event of a clinically 
meaningful finding. Then, a reason-
able follow-up to identifying an action-
able variant in the course of a research 
project would be to recommend that a 
patient specimen be retested in the set-
ting of an accredited clinical laboratory 
that offers the test and genetic counsel-
ing as to the meaning of the results.
Aliccia Bollig-Fischer, PhD
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To the Editor:
I commend Ichihara et al.1 for 
their excellent article entitled “Phase 
II trial of gefitinib in combination with 
bevacizumab as first-line therapy for 
advanced non–small cell lung cancer 
specific due to particular histological 
subtypes and different genetic muta-
tions. Therefore, it is essential to con-
duct a further evaluation to define an 
acceptable cost-effectiveness standard 
of bevacizumab or gefitinib, in different 
region for patients with NSCLC.
Finally, although the use of beva-
cizumab may have an effective influence 
in combination with gefitinib, recur-
rence is frequently occurred. Food and 
Drug Administration has abrogated bev-
acizumab in the breast cancer, because 
of lacking the solid proof of increasing 
survival rates.5 According to a recent 
study conducted by Schwaederlé et al.,6 
TP53 mutations are associated with 
higher vascular endothelial growth 
factor-A expression, which is a func-
tional target of bevacizumab. In this 
case, bevacizumab treatment may have 
more chance to reduce the recurrence 
due to the TP53 mutations. What exact 
medication should bevacizumab to 
combine with to overcome the recur-
rence? Future studies need to focus on 
identifying predictive biomarkers of 
recurrence and design targeted thera-
pies based on these findings.
Xiaoshen Zhang, MD
Tongji University Cancer Institute 
Tongji University School of Medicine
Shanghai, China 
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